Other Medications Showing Risk Signals
Several other drug classes have been flagged in recent research, though the evidence is less consistent or more preliminary.
1. Psychotropic Medications
| Class | Examples | Risk |
|---|---|---|
| Benzodiazepines | Diazepam, Lorazepam, Alprazolam | Linked to cognitive impairment, especially in older adults |
| Antidepressants | SSRIs, tricyclics | Some studies show association; more research needed |
| Antipsychotics | Quetiapine, Clozapine | Well-documented link to cognitive decline; often used off-label for dementia symptoms |
Key insight: These medications are often prescribed 1–2 years before a dementia diagnosis, suggesting the relationship may be complex and not purely causal.
2. Pain Medications
| Drug | Risk Signal |
|---|---|
| Tramadol | A 2025 analysis of FDA adverse event data identified tramadol among the top 50 drugs with high dementia risk signals |
| Opioids | Long-term use has been associated with cognitive decline in some studies |
3. Other High-Risk Classes
A 2025 case-control study highlighted several medication classes that may contribute to adverse cognitive outcomes, especially when used concurrently:
| Class | Examples |
|---|---|
| Opioids | Morphine, Oxycodone, Hydrocodone |
| Corticosteroids | Prednisone, Hydrocortisone |
| Anticonvulsants | Valproate, Gabapentin, Topiramate |
4. Drugs with Correlated Gene Expression
Advanced genetic analysis has linked the target genes of several drugs to dementia, suggesting a potential biological connection:
| Drug | Primary Use |
|---|---|
| Quetiapine | Antipsychotic |
| Clozapine | Antipsychotic |
| Valproic acid | Seizures, mood stabilizer |
| Alendronate | Osteoporosis |
| Digoxin | Heart failure, atrial fibrillation |
Understanding the Risk: Not All Drugs Are Equal
| Factor | How It Affects Risk |
|---|---|
| Type of drug | Some drugs (oxybutynin, tolterodine) show stronger links than others |
| Dose | Higher doses carry greater risk |
| Duration | Long-term use (months to years) is more concerning than short-term use |
| Patient age | Risk is most significant in adults over 55 |
| Concurrent use | Taking multiple anticholinergics increases the “anticholinergic burden” |
| Brain health | Existing cognitive impairment may increase vulnerability |
